Related Experiment Video

Updated: Aug 14, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Transforming growth factor-beta and malignant melanoma: molecular mechanisms

Mahmoud R Hussein1

  • 1Department of Pathology, School of Medicine, Assuit University, Assuit, Egypt. mrh17@swissinfo.org

Journal of Cutaneous Pathology
|June 15, 2005
PubMed

Insights

Transforming growth factor-beta (TGF-beta) has dual roles in cancer. This review explores how melanoma cells evade TGF-beta

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor-beta (TGF-beta) signaling is crucial in cellular processes, exhibiting both tumor-suppressive and oncogenic functions.
  • TGF-beta exerts its effects by binding to cell surface receptors, initiating a cascade that involves SMAD proteins and transcriptional regulation.
  • Malignant cells often evade TGF-beta's tumor-suppressive actions through alterations in the TGF-beta signaling pathway.

Purpose of the Study:

  • To review the current understanding of the TGF-beta receptor/SMAD signaling pathway in melanoma.
  • To investigate the roles of specific genes, including SMADs, SKI, Filamin, endoglin, and Follistatin, within the context of melanoma.

Main Methods:

  • Literature review of existing research on TGF-beta signaling and melanoma.
  • Analysis of molecular components involved in the TGF-beta pathway and their alterations in melanoma cells.

Main Results:

  • Melanoma cells demonstrate resistance to the tumor-suppressive effects of TGF-beta.
  • No apparent defects in the TGF-beta receptor/SMAD pathway components were identified in melanoma.
  • TGF-beta may exert its effects in melanoma independently of the canonical receptor/SMAD pathway.

Conclusions:

  • Melanoma's resistance to TGF-beta suggests alternative signaling mechanisms may be involved.
  • Further research into non-canonical TGF-beta pathways and related molecules in melanoma is warranted.
  • Understanding these mechanisms could reveal novel therapeutic targets for melanoma treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...